New combo therapy shows promise for Hard-to-Treat cancers
NCT ID NCT02856425
First seen Jan 22, 2026 · Last updated May 19, 2026 · Updated 19 times
Summary
This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (an anti-angiogenesis drug)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nintedanib when given with pembrolizumab. The approach aims to see if blocking blood vessel growth can help the immune system fight cancer more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH ANY ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Léon Bérard
Lyon, 69008, France
-
Gustave Roussy
Villejuif, Val De Marne, 94805, France
-
Hôpital Bichat
Paris, 75018, France
-
IUCT--O
Toulouse, 31059, France
-
Institut Bergonié
Bordeaux, 33000, France
Conditions
Explore the condition pages connected to this study.